These results indicate that CML LT-HSCs with low or absent c-KIT expression represent a TKI-resistant subpopulation and are consistent with the observation that primitive CD34+ cells that persist in CML patients on TKI treatment are characterized by lack of c-KIT expression (42). This evidence concerns the gene KIT and chronic myelogenous leukemia, BCR-ABL1 positive.